Image 1
Reclipsen Kit
Product Images NDC 0093-3304
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Reclipsen (NDC 0093-3304). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image 2
Image 3
Image 4
Image 5
Image 6
Reclipsen is a combination hormonal medication containing desogestrel and ethinyl estradiol tablets that are used for birth control in women. The tablets are available in the strength of 0.15 mg/0.03 mg and are usually taken once a day as prescribed. The medication should be stored at a controlled room temperature between 20° to 25°C (68° to 77°F) and kept out of the reach of children. The package insert provides information for the dispenser, and one combination labeling piece of information intended for the patient is included in each prescription. Reclipsen is a Teva product.*
Image 7
Reclipsen is a combination of desogestrel and ethinyl estradiol, which are used in the form of tablets for oral contraception. The product is specifically intended for the prevention of pregnancy and not for the protection of individuals against any sexually transmitted diseases or HIV infection. The tablet is identifiable through the GTIN code 0000333304160 and each rose-colored tablet contains 0.15mg of desogestrel and 0.03mg of ethinyl estradiol, while the white tablets are composed of inert ingredients.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
